Evidence map›Paper›PMID 38689252›Full record

ArticleBMC cancer2024

Identification of prognostic signatures in remnant gastric cancer through an interpretable risk model based on machine learning: a multicenter cohort study.

Zhouwei Zhan, Bijuan Chen, Hui Cheng, Shaohua Xu, Chunping Huang, Sijing Zhou, Haiting Chen, Xuanping Lin, Ruyu Lin, Wanting Huang and 7 more

Abstract readMulticenter Study
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zhouwei Zhan *Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, Fujian, 350014, People's Republic of China.
Bijuan Chen *Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, 350014, People's Republic of China.
Hui Cheng *Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, People's Republic of China.
Shaohua XuDepartment of Hepatobiliary and Pancreatic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, 350014, People's Republic of China.
Chunping HuangDepartment of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, 350014, People's Republic of China.
Sijing ZhouDepartment of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, Fujian, 350014, People's Republic of China.
Haiting ChenSchool of Basic Medical Sciences of Fujian Medical University, Fuzhou, Fujian, 350004, People's Republic of China.
Xuanping LinSchool of Basic Medical Sciences of Fujian Medical University, Fuzhou, Fujian, 350004, People's Republic of China.
Ruyu LinSchool of Basic Medical Sciences of Fujian Medical University, Fuzhou, Fujian, 350004, People's Republic of China.
Wanting HuangSchool of Basic Medical Sciences of Fujian Medical University, Fuzhou, Fujian, 350004, People's Republic of China.
Xiaohuan MaSchool of Basic Medical Sciences of Fujian Medical University, Fuzhou, Fujian, 350004, People's Republic of China.
Yu FuSchool of Basic Medical Sciences of Fujian Medical University, Fuzhou, Fujian, 350004, People's Republic of China.
Zhipeng ChenSchool of Basic Medical Sciences of Fujian Medical University, Fuzhou, Fujian, 350004, People's Republic of China.
Hanchen ZhengDepartment of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, Fujian, 350014, People's Republic of China.
Songchang Shi *Department of Critical Care Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital South Branch, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, People's Republic of China. songchangshi81@163.com.
Zengqing Guo *Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, Fujian, 350014, People's Republic of China. gzq_005@126.com.
Lihui Zhang *Department of Critical Care Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital South Branch, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, People's Republic of China. 1299143079@qq.com.

Funding

Joint Funds for the innovation of science and Technology, Fujian province 2021Y9204
6 · The paper itself

Abstract

objectiveThe purpose of this study was to develop an individual survival prediction model based on multiple machine learning (ML) algorithms to predict survival probability for remnant gastric cancer (RGC).

methodsClinicopathologic data of 286 patients with RGC undergoing operation (radical resection and palliative resection) from a multi-institution database were enrolled and analyzed retrospectively. These individuals were split into training (80%) and test cohort (20%) by using random allocation. Nine commonly used ML methods were employed to construct survival prediction models. Algorithm performance was estimated by analyzing accuracy, precision, recall, F1-score, area under the receiver operating characteristic curve (AUC), confusion matrices, five-fold cross-validation, decision curve analysis (DCA), and calibration curve. The best model was selected through appropriate verification and validation and was suitably explained by the SHapley Additive exPlanations (SHAP) approach.

resultsCompared with the traditional methods, the RGC survival prediction models employing ML exhibited good performance. Except for the decision tree model, all other models performed well, with a mean ROC AUC above 0.7. The DCA findings suggest that the developed models have the potential to enhance clinical decision-making processes, thereby improving patient outcomes. The calibration curve reveals that all models except the decision tree model displayed commendable predictive performance. Through CatBoost-based modeling and SHAP analysis, the five-year survival probability is significantly influenced by several factors: the lymph node ratio (LNR), T stage, tumor size, resection margins, perineural invasion, and distant metastasis.

conclusionsThis study established predictive models for survival probability at five years in RGC patients based on ML algorithms which showed high accuracy and applicative value.

Indexed as

Machine LearningStomach NeoplasmsAgedAlgorithmsFemaleGastrectomyGastric StumpHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk AssessmentROC CurveInterpretableMachine learningMulticenterPrediction modelPrognosisRemnant gastric cancer

Identifiers

PMID38689252
PMCPMC11062017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.